Suri Biotech

SURI BioTech, a Swiss biotechnology firm established in March 2023, operates as a recognized spin-off from ETH Zürich. The company was founded by CEO Dr. sc. Vanesa Rocha Martin, who has dedicated over 13 years to studying gut microbes and their impact on health, particularly during her PhD research at ETH Zürich. Her scientific background in veterinary and food sciences, combined with a need for financial expertise, led her to bring on Mathilde Dupin as a co-founder. The company name, SURI, is a nod to both the city of its origin, Zürich (“Tsüri”), and Dr. Rocha Martin's Argentinian heritage, where 'Suri' relates to fertility.

SURI BioTech focuses on developing and commercializing microbiome solutions, specifically health-promoting bacterial strains with proven mechanisms of action. The company employs a proprietary R&D platform to screen, identify, and test bacterial strains based on their metabolic capacity to ensure targeted performance. Its business model involves selling these proprietary strains either in bulk or as finished products, targeting businesses such as distributors and ingredient manufacturers. The firm also provides regulatory support and marketing guidelines for its clients. The company operates in the growing probiotic supplements market, which is projected to expand significantly due to demand for science-based formulas.

The product portfolio includes probiotics for mothers and babies, designed to support proper intestinal metabolism and gut colonization. A lead candidate, BactoKind™, is a probiotic food supplement in development aimed at alleviating infant colic by reducing intestinal gas production. Another product, RecoBiotic, is designed for athletes to help metabolize lactic acid post-exercise. The company’s strains have Qualified Presumption of Safety (QPS) status in the European Union, are produced with standard manufacturing practices ensuring scalability, and have a guaranteed shelf-life of 24 months at room temperature. As a pre-seed stage company, SURI BioTech has secured approximately CHF 800k in public and philanthropic grants and CHF 200k in a convertible loan.

Keywords: microbiome solutions, probiotics, bacterial strains, gut health, infant colic, sports nutrition, biotechnology, ETH Zürich spin-off, B2B ingredients, food supplements, Vanesa Rocha Martin, BactoKind, RecoBiotic, gut microbiome, metabolic activity, microbial seeding, infant health, athlete performance, dietary supplements, health and wellness